Clinic
Gibson General Hospital INC.
Gibson General Hospital INC. was paid $4.42M by Medicaid between Jan 2018 and Nov 2024, across 112 billing codes. Its largest line is 99284, emergency room visit (serious) — 30% of everything it billed.
33Billing provider infoGIBSON GENERAL HOSPITAL INC.
PRINCETON, IN 47670
PRINCETON, IN 47670
33aNPI1558346007assigned 12/07/2005
33bProvider typeCritical Access Hospital Clinic/Center
28Total paid$4.42M
24GClaims90,692
24DCodes billed112
24AFirst – last monthJan 2018 – Nov 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 8,716 | $180K | |
| 2019 | 7,998 | $274K | |
| 2020 | 9,576 | $478K | |
| 2021 | 17,992 | $787K | |
| 2022 | 20,742 | $1.08M | |
| 2023 | 14,997 | $950K | |
| 2024incomplete | 10,671 | $677K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 30% | 9,119 | 7,621 | $1.35M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 29% | 9,880 | 8,609 | $1.26M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 5.7% | 3,730 | 3,056 | $254K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 3.4% | 1,886 | 1,495 | $152K |
| 99221 | 3.2% | 343 | 286 | $142K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.8% | 1,395 | 1,179 | $124K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2.7% | 1,697 | 1,480 | $120K |
| 71045 | Radiologic examination, chest; single view | 2.6% | 1,068 | 837 | $114K |
| 99239 | Hospital discharge day management, more than 30 minutes | 2.4% | 317 | 276 | $108K |
| 99218 | 2.1% | 362 | 204 | $93K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.0% | 1,514 | 1,122 | $89K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.8% | 498 | 447 | $80K |
100 more codes
| 99285 | Emergency room visit (most serious) | 1.5% | 830 | $68K |
| 99217 | 1.3% | 235 | $59K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.2% | 1,807 | $52K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 12,346 | $51K |
| 80053 | Comprehensive metabolic panel | 1.1% | 9,452 | $50K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,017 | $41K |
| 36415 | Collection of venous blood by venipuncture | <1% | 15,094 | $32K |
| 73630 | <1% | 883 | $31K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 146 | $22K |
| G0378 | Hospital observation service, per hour | <1% | 280 | $13K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 64 | $12K |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 21 | $11K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 252 | $9K |
| 81001 | <1% | 3,457 | $8K | |
| 84484 | <1% | 987 | $7K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 226 | $6K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 279 | $6K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 184 | $6K |
| 80050 | General health panel | <1% | 37 | $5K |
| 83735 | <1% | 1,471 | $5K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 16 | $4K |
| 83605 | <1% | 578 | $4K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 572 | $3K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 150 | $3K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 304 | $3K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 92 | $3K |
| 84100 | <1% | 1,087 | $3K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 484 | $2K |
| 80061 | Lipid panel | <1% | 225 | $2K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 12 | $2K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 80 | $1K |
| 85610 | <1% | 521 | $1K | |
| 83690 | <1% | 274 | $1K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 66 | $1K |
| 80306 | <1% | 107 | $1K | |
| 87040 | <1% | 220 | $1K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 395 | $1K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 307 | $985.64 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 57 | $745.09 |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 22 | $722.36 |
| 87430 | <1% | 118 | $558.68 | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 45 | $543.03 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 95 | $470.50 |
| 84145 | <1% | 32 | $389.54 | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 12 | $386.66 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 31 | $260.21 |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 149 | $230.32 |
| 81003 | <1% | 364 | $214.14 | |
| 86140 | <1% | 66 | $203.63 | |
| 86376 | <1% | 16 | $172.97 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 19 | $167.62 |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | <1% | 99 | $161.79 |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 314 | $159.69 |
| 85379 | <1% | 12 | $104.54 | |
| 87807 | <1% | 14 | $104.43 | |
| 87081 | <1% | 32 | $94.21 | |
| 82553 | <1% | 29 | $69.90 | |
| 80331 | <1% | 19 | $65.24 | |
| J3490 | Unclassified drugs | <1% | 153 | $27.92 |
| 80366 | <1% | 18 | $17.02 | |
| 80373 | <1% | 18 | $17.02 | |
| 80344 | <1% | 18 | $17.02 | |
| 80355 | <1% | 18 | $17.02 | |
| 80377 | <1% | 18 | $17.02 | |
| 80338 | <1% | 18 | $17.02 | |
| 80372 | <1% | 18 | $17.02 | |
| 80337 | <1% | 18 | $17.02 | |
| 80370 | <1% | 18 | $17.02 | |
| 80334 | <1% | 18 | $17.02 | |
| 80357 | <1% | 18 | $17.02 | |
| 80341 | <1% | 18 | $17.02 | |
| 80368 | <1% | 18 | $17.02 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 192 | $0.00 |
| 80360 | 0% | 18 | $0.00 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 92 | $0.00 |
| 80361 | 0% | 18 | $0.00 | |
| 82570 | 0% | 18 | $0.00 | |
| 80348 | 0% | 18 | $0.00 | |
| 80326 | 0% | 18 | $0.00 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 31 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 109 | $0.00 |
| 80354 | 0% | 18 | $0.00 | |
| 80365 | 0% | 18 | $0.00 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 15 | $0.00 |
| 80364 | 0% | 18 | $0.00 | |
| 83992 | 0% | 18 | $0.00 | |
| 80346 | 0% | 18 | $0.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 127 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 360 | $0.00 |
| 80359 | 0% | 18 | $0.00 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 19 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 28 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 16 | $0.00 |
| 80353 | 0% | 18 | $0.00 | |
| J2704 | Injection, propofol, 10 mg | 0% | 89 | $0.00 |
| 80367 | 0% | 18 | $0.00 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 28 | $0.00 |
| 80358 | 0% | 18 | $0.00 | |
| 80371 | 0% | 18 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMORGAN, LOIS (VICE PRESIDENT AND CNO)
| Provider | Location | Paid |
|---|---|---|
| Gibson General Hospital INC | Princeton, IN | $560K |
| Gibson General Hospital, INC | Princeton, IN | $197K |
| Gibson General Hospital, INC | Fort Branch, IN | $105K |
| Gibson General Hospital, INC | Princeton, IN | $77K |
| Gibson General Hospital, INC | Newburgh, IN | $32K |
| Gibson General Hospital, INC | Princeton, IN | $25K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.